Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-centeR, Randomized, DoUBle-Masked, Placebo-Controlled StudY to Evaluate the Clinical Safety and Efficacy of OKG-0301 in the Treatment of Acute Adenoviral Conjunctivitis

Next Previous
Trial Profile

A Phase 2, Multi-centeR, Randomized, DoUBle-Masked, Placebo-Controlled StudY to Evaluate the Clinical Safety and Efficacy of OKG-0301 in the Treatment of Acute Adenoviral Conjunctivitis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranpirnase (Primary)
  • Indications Adenovirus infections; Infectious conjunctivitis; Viral-conjunctivitis
  • Focus Therapeutic Use
  • Acronyms RUBY
  • Sponsors Okogen

Most Recent Events

  • 20 Apr 2022 Planned End Date changed from 30 Jun 2021 to 30 Jun 2022.
  • 20 Apr 2022 Planned primary completion date changed from 30 Jun 2021 to 30 Jun 2022.
  • 29 Apr 2021 According to an Okogen media release, data from this trial will be presented by Professor Stephanie Watson in greater detail at the ARVO virtual annual meeting, May 1-7, 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top